Supplemental Triple Antioxidant Therapy as a Treatment for Anoctamin 5 Deficient Muscular Dystrophies
- Detailed Technology Description
- The current invention uses triple anti-oxidant therapy to reverse mitochondrial damage and correct exercise intolerance in Limb-girdle muscular dystrophy 2L.
- Countries
- Not Available
- Application No.
- None
- *Abstract
-
Limb-girdle muscular dystrophy 2L (LGMD2L) is a progressive disease that results in muscle weakness, pain and exercise intolerance. There is currently no treatment for LGMD2L. Researchers at Nationwide Children's Hospital have found that impaired mitochondrial function results in disease pathogenesis. The current invention uses triple anti-oxidant therapy to reverse mitochondrial damage and correct exercise intolerance. Because LGMD2L is slowly progressive, this treatment can delay disease progression, either alone or in conjunction with gene therapy.
- *Inquiry
- Margaret Barkett, PhD Senior Licensing Associate The Research Institute at Nationwide Children's Hospital 700 Children's Drive, Columbus, OH 43205 Phone: (614) 355-2957 Margaret.Barkett@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- Country/Region
- USA
For more information, please click Here
